Description
Phenylpiracetam Hydrazide Tablets
| Phenylpiracetam Hydrazide | |
| CAS Number | 77472-70-9 |
| Molar Mass | 218.256 g·mol−1 |
| Chemical Formula | C12H14N2O2 |
| IUPAC Name | (R,S)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide |
Introduction
Phenylpiracetam Hydrazine Tablets are an innovative research compound designed for scientific investigations, specifically focusing on its potential applications in neuroscience. It is imperative to emphasize that these tablets are intended solely for research purposes, and any mention of human consumption is strictly prohibited.
Key Characteristics
Phenylpiracetam Hydrazine is a derivative of phenylpiracetam, a well-known nootropic compound. This tablet formulation offers unique characteristics that make it suitable for research exploring its impact on neurotransmitters, brain function, and related areas of study.
Research Applications
Researchers utilize Phenylpiracetam Hydrazine Tablets as a tool to investigate its applications in neuroscience. The tablet form facilitates precise dosage control, enabling studies on its potential effects on neurotransmitter regulation, neurological disorders, and related research areas.
Research Benefits
Phenylpiracetam Hydrazide and Dopamine
Studies suggest a potential link between Phenylpiracetam Hydrazine and dopamine regulation. The research aims to elucidate how the compound may influence dopamine levels in the brain, providing insights into its potential role in neurotransmitter modulation.
Phenylpiracetam Hydrazide and Potential Application on Stroke
Investigations explore the potential neuroprotective effects of Phenylpiracetam Hydrazine, particularly in the context of stroke. Researchers aim to understand its impact on neuronal health and recovery post-stroke, contributing to the development of novel therapeutic approaches.
Phenylpiracetam Hydrazide and Depression
The compound’s potential effects on mood and mental well-being are under scrutiny in studies related to depression. Research examines whether Phenylpiracetam Hydrazine may have antidepressant properties, shedding light on its potential applications in mental health research.
Summary
Phenylpiracetam Hydrazine Tablets offer a platform for research into its potential benefits, including dopamine regulation, neuroprotection post-stroke, and its impact on depressive-like conditions. As a research tool, this tablet formulation contributes to expanding our understanding of the compound’s effects on neurological processes.
Disclaimer
This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.
Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).
Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.
Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].
IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.
References
- Urban KR, Gao WJ. Performance enhancement at the cost of potential brain plasticity: neural ramifications of nootropic drugs in the healthy developing brain. Front Syst Neurosci. 2014 May 13;8:38. doi: 10.3389/fnsys.2014.00038. PMID: 24860437; PMCID: PMC4026746. [Read More].
- Koval’chuk VV, Skoromets AA, Koval’chuk IV, Stoianova EG, Vysotskaia ML, Melikhova EV, Il’iaĭnen EV. [Efficacy of phenotropil in the rehabilitation of stroke patients]. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12 Pt 2):38-40. Russian. PMID: 21626817. [Read More].
- Savchenko AIu, Zakharova NS, Stepanov IN. [The phenotropil treatment of the consequences of brain organic lesions]. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(12):22-6. Russian. PMID: 16447562. [Read More].
Reviews
There are no reviews yet.